COMORBIDITY 2009 <777>
Database EMBASE
Accession Number 0019828034
Authors Dausey D.J. Pincus H.A. Herrell J.M.
Institution
(Dausey) Carnegie Mellon University, Pittsburgh PA 15213, United States.
(Dausey, Pincus) RAND Corporation, Pittsburgh PA 15213, United States.
(Pincus) College of Physicians and Surgeons, Columbia University, New York Presbyterian Hospital and Irving
Center for Clinical and Translational Research, New York NY 10032, United States.
(Herrell) Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse
Treatment (CSAT), Rockville, MD 20850, United States.
Country of Publication
United Kingdom
Title
Performance measurement for co-occurring mental health and substance use
disorders.
Source
Substance Abuse: Treatment, Prevention, and Policy. 4(pp 18), 2009. Article Number:
1747. Date of Publication: 14 Oct 2009.
Publisher
BioMed Central Ltd.
Abstract
Background: Co-occurring mental health and substance use disorders (COD) are the norm
rather than the exception. It is therefore critical that performance measures are developed to
assess the quality of care for individuals with COD irrespective of whether they seek care in
mental health systems or substance abuse systems or both. Methods: We convened an
expert panel and asked them to rate a series of structure, process, and outcomes measures
for COD using a structured evaluation tool with domains for importance, usefulness, validity,
and practicality. Results: We chose twelve measures that demonstrated promise for future
pilot testing and refinement. The criteria that we applied to select these measures included:
balance across structure, process, and outcome measures, quantitative ratings from the
panelists, narrative comments from the panelists, and evidence the measure had been tested
in a similar form elsewhere. Conclusion: To be successful performance measures need to be
developed in such a way that they align with needs of administrators and providers.
Policymakers need to work with all stakeholders to establish a concrete agenda for
developing, piloting and implementing performance measures that include COD. Future
research could begin to consider strategies that increase our ability to use administrative
coding in mental health and substance use disorder systems to efficiently capture quality
relevant clinical data. copyright 2009 Dausey et al; licensee BioMed Central Ltd.
Publication Type Journal: Article
Journal Name Substance Abuse: Treatment, Prevention, and Policy
Volume 4
Page 18
Year of Publication 2009
Date of Publication 14 Oct 2009
COMORBIDITY 2009 <801>
Database EMBASE
Accession Number 0019813108
Authors Schneider B.
Institution
(Schneider) Center of Psychiatry, Department for Psychiatry, Psychosomatics, and Psychotherapy, GoetheUniversity, Heinrich-Hoffmann-Str. 10, 60528 Frankfurt, Germany.
Country of Publication
United Kingdom
Title
Substance use disorders and risk for completed suicide.
Source
Archives of Suicide Research. 13(4)(pp 303-316), 2009. Date of Publication: October 2009.
Publisher
Routledge
Abstract
Substance use disorders are among the most frequent psychiatric disorders found in
suicides. In psychological autopsy studies between 19% and 63% of all suicides suffered from
substance use disorders, mostly from alcohol use disorders. Suicide risk is highly increased in
substance use disorders, particularly in alcohol use disorders, and in co-morbid alcoholism
and depression. So far, some risk factors for suicide have been identified in alcoholism.
Nevertheless, various questions about the relationship between substance use disorders and
suicide remain open, which indicate directions for future research. copyright International
Academy for Suicide Research.
ISSN 1381-1118
Publication Type Journal: Article
Journal Name Archives of Suicide Research
Volume 13
Issue Part 4
Page 303-316
Year of Publication 2009
Date of Publication October 2009
COMORBIDITY 2009 <802>
Database EMBASE
Accession Number 0019813114
Authors van Tuan N. Dalman C. Thiem N.V. Nghi T.V. Allebeck P.
Institution
(van Tuan, Dalman, Allebeck) Department of Public Health Sciences, Karolinska Institute, Stockholm, Sweden.
(van Tuan, Thiem, Nghi) Department of Psychiatry, Hanoi Medical University, Hanoi, Vietnam.
(van Tuan, Thiem, Nghi) National Institute of Mental Health, Hanoi, Vietnam.
Country of Publication
United Kingdom
Title
Suicide attempts by poisoning in Hanoi, Vietnam: Methods used, mental problems,
and history of mental health care.
Source
Archives of Suicide Research. 13(4)(pp 368-377), 2009. Date of Publication: October 2009.
Publisher
Routledge
Abstract
The objective of this paper was to investigate methods of poisoning, presence of mental
problems, and the rate of psychiatric care among suicide attempters in Vietnam. Three
hundred and nine suicide attempters by poisoning admitted to Bach Mai Hospital's Poison
Control Center were investigated by trained nurses and qualified psychiatrists. Standardized
questionnaires were used to assess methods of suicide, presence of mental problems, and
psychiatric care. The most common methods were poisoning by psychotropic drugs in urban,
and pesticides in rural areas. ICD-10 confirmed disorders were present in 68% of the cases
and 73% rated positive on SRQ-20. Most patients were not in contact with psychiatric care.
Restrictions on availability and handling of drugs and pesticides should be reinforced. Better
infrastructures are needed for identification and treatment of persons with mental disorders.
copyright International Academy for Suicide Research.
ISSN 1381-1118
Publication Type Journal: Article
Journal Name Archives of Suicide Research
Volume 13
Issue Part 4
Page 368-377
Year of Publication 2009
Date of Publication October 2009
COMORBIDITY 2009 <925>
Database EMBASE
Accession Number 0019401946
Authors Nery-Fernandes F. Quarantini L.C. Galvao-De-Almeida A. Rocha M.V. Kapczinski F. Miranda-Scippa A.
Institution
(Nery-Fernandes, Quarantini, Galvao-De-Almeida, Rocha, Kapczinski, Miranda-Scippa) Center for Study and
Treatment of Affective Disorders (CETTA), Universidade Federal da Bahia, Salvador-Ba, Brazil.
Country of Publication
United Kingdom
Title
Lower rates of comorbidities in euthymic bipolar patients..
Source
The world journal of biological psychiatry : the official journal of the World Federation of
Societies of Biological Psychiatry. 10(4 Pt 2)(pp 474-479), 2009. Date of Publication: 2009.
Abstract
OBJECTIVE: This study assessed the frequency of axis I psychiatric comorbidities in
euthymic bipolar patients and the clinical differences between patients with and without
comorbidities. METHOD: In this study, 62 euthymic bipolar outpatients assessed using a
clinical questionnaire underwent a structured diagnostic interview (SCID/CV-DSM-IV) as well
as a symptoms evaluation (YMRS and HAM-D-17). RESULTS: The lifetime frequency of
patients with comorbidities was 27.4%. The most frequent comorbidities were anxiety
disorders (33.7%), and the positive associated variables were more advanced age, the
presence of a steady partner, a first episode of the depressive type and lifetime attempted
suicide. CONCLUSIONS: The lower frequency of comorbidities found in our study in
comparison with those described in the literature may be due to the evaluation restricted only
to euthymic patients. This suggests the importance of assessing psychiatric comorbidity in
bipolar individuals while not in acute phases of the disorder.
Publication Type Journal: Article
Journal Name The world journal of biological psychiatry : the official journal of the World Federation of Societies of
Biological Psychiatry
Volume 10
Issue Part 4 Pt 2
Page 474-479
Year of Publication 2009
Date of Publication 2009
COMORBIDITY 2009 <926>
Database EMBASE
Accession Number 0017853283
Authors Sorensen H.J. Mortensen E.L. Reinisch J.M. Mednick S.A.
Institution
(Sorensen, Mortensen, Reinisch, Mednick) Danish Epidemiology Science Center, Institute of Preventive Medicine,
Copenhagen University Hospital, Copenhagen, Denmark.
Country of Publication
United Kingdom
Title
Parental psychiatric hospitalisation and offspring schizophrenia..
Source
The world journal of biological psychiatry : the official journal of the World Federation of
Societies of Biological Psychiatry. 10(4 Pt 2)(pp 571-575), 2009. Date of Publication: 2009.
Abstract
The risk of schizophrenia has been linked with a family history of schizophrenia and less
strongly with other psychiatric disorders in family members. Using data from the Copenhagen
Perinatal Cohort and from the Danish Psychiatric Case Register, we studied the relationship
between offspring risk of schizophrenia and a range of psychotic and non-psychotic
psychiatric diagnoses in parents. Psychiatric admission data after 1969 were available for
7047 cohort members born between 1959 and 1961, and for 7006 mothers and 6993 fathers.
Univariate analysis showed that neurosis, alcohol and substance dependence in both parents
were associated with elevated risk of offspring schizophrenia; in addition, maternal
schizophrenia, affective disorder and personality disorder were associated with elevated risk.
Controlling for parental age, parental social status, and parental psychiatric co-diagnosis,
offspring risk of schizophrenia was associated with maternal schizophrenia (OR = 15.41 with
95% CI 5.96-39.81) and, independently, with paternal hospitalisation with neurosis (OR =
5.90 with 95% CI 2.23-15.62). The risk of schizophrenia associated with paternal neurosis
remained significant after excluding offspring of parents with non-affective psychosis from the
sample. These findings suggest that genetic and family studies should not only focus on
parental history of schizophrenia since the simple distinction between positive and negative
family history could not accurately describe offspring risk in this sample.
Publication Type Journal: Article
Journal Name The world journal of biological psychiatry : the official journal of the World Federation of Societies of
Biological Psychiatry
Volume 10
Issue Part 4 Pt 2
Page 571-575
Year of Publication 2009
Date of Publication 2009
COMORBIDITY 2009 <949>
Database EMBASE
Accession Number 0019658047
Authors Novak G. Boukhadra J. Shaikh S.A. Kennedy J.L. Le Foll B.
Institution
(Novak, Boukhadra, Shaikh, Kennedy, Le Foll) Translational Addiction Research Laboratory, Centre for Addiction
and Mental Health and The University of Toronto, Toronto, Ontario, Canada.
Country of Publication
United Kingdom
Title
Association of a polymorphism in the NRXN3 gene with the degree of smoking in
schizophrenia: a preliminary study.
Source
The world journal of biological psychiatry : the official journal of the World Federation of
Societies of Biological Psychiatry. 10(4 Pt 3)(pp 929-935), 2009. Date of Publication: 2009.
Abstract
Whole genome scan studies have recently identified the NRXN1 and NRXN3 genes as
potential contributing factors in the risk for nicotine addiction. We have genotyped 15 single
nucleotide polymorphisms (SNPs) spanning the NRXN1 and NRXN3 genes in 195 unrelated
patients with schizophrenia for whom information about their smoking status and number of
cigarettes smoked per day (CPD) was obtained. The NRXN3 marker rs1004212 was
significantly associated with quantity of tobacco smoked. Individuals homozygous for the C
allele of rs1004212 smoked more cigarettes per day than heterozygous individuals. We found
no significant association of markers within the NRXN1 gene with the risk of smoking or the
quantity of tobacco smoked. Because of the relatively small sample size, this is a preliminary
study. However, this candidate gene study supports the observations of molecular studies
implicating the NRXN genes in drug addiction and suggests that variants in the NRXN3 gene
could contribute to the degree of nicotine dependence in patients with schizophrenia.
Publication Type Journal: Article
Journal Name The world journal of biological psychiatry : the official journal of the World Federation of Societies of
Biological Psychiatry
Volume 10
Issue Part 4 Pt 3
Page 929-935
Year of Publication 2009
Date of Publication 2009
COMORBIDITY 2009 <950>
Database EMBASE
Accession Number 0018609413
Authors Fontenelle L.F. Mendlowicz M.V. Versiani M.
Institution
(Fontenelle, Mendlowicz, Versiani) Anxiety and Depression Research Program, Institute of Psychiatry, Universidade
Federal do Rio de Janeiro (IPUB/UFRJ), Rio de Janeiro, RJ, Brazil.
Country of Publication
United Kingdom
Title
Volitional disorders: a proposal for DSM-V..
Source
The world journal of biological psychiatry : the official journal of the World Federation of
Societies of Biological Psychiatry. 10(4 Pt 3)(pp 1016-1029), 2009. Date of Publication: 2009.
Abstract
In the DSM-IV-TR, specific impulse control disorders not elsewhere classified (ICD) have
been designated following four principles: (1) through the addition of an adjective that
emphasizes the aberrant character of an otherwise normal behaviour (e.g., pathological
gambling); (2) by means of metaphors (such as in intermittent explosive disorder); (3)
according to the presumably quintessential nature of their main signs and symptoms, such as
impulsive (e.g., impulse control disorders not elsewhere classified), compulsive (e.g.,
compulsive shopping), or addictive (e.g., internet addiction); or (4) using Greek suffix mania
(e.g., kleptomania, pyromania, and trichotillomania). Given this flagrant inconsistency, we
argue that time has come to adopt a less arbitrary way of describing these disorders, at least
until it becomes clearer whether they are really impulsive, compulsive or addictive or if the
preoccupation with this distinction is valid. In keeping with DSM's emphasis on descriptive
phenomenology rather than on unsupported theory, a less biased terminology is in order.
Therefore, we would like to suggest: (1) the substitution of the term ICD by the more neutral
expression 'volitional disorders not elsewhere classified'; (2) the use of the classical Greek
suffix mania, already present in some DSM-IV-TR ICDs, as the main naming principle to be
adopted in the DSM-V; and (3) the creation of compulsive, impulsive, and mixed subtypes of
the 'volitional disorders not elsewhere classified', since they are beginning to be validated by
treatment trials.
Publication Type Journal: Review
Journal Name The world journal of biological psychiatry : the official journal of the World Federation of Societies of
Biological Psychiatry
Volume 10
Issue Part 4 Pt 3
Page 1016-1029
Year of Publication 2009
Date of Publication 2009
COMORBIDITY 2009 <970>
Database EMBASE
Accession Number 0020021664
Authors Shi L. Ascher-Svanum H. Chiang Y.J. Zhao Y. Fonseca V. Winstead D.
Institution
(Shi, Ascher-Svanum, Chiang, Zhao, Fonseca, Winstead) School of Public Health and Tropical Medicine, Tulane
University, 1440 Canal Street, New Orleans, LA 70112, USA.
Country of Publication
United Kingdom
Title
Predictors of metabolic monitoring among schizophrenia patients with a new episode
of second-generation antipsychotic use in the Veterans Health Administration..
Source
BMC psychiatry. 9(pp 80), 2009. Date of Publication: 2009.
Abstract
BACKGROUND: To examine the baseline metabolic monitoring (MetMon) for second
generation antipsychotics (SGA) among patients with schizophrenia in the Veterans
Integrated Service Network (VISN) 16 of the Veterans Health Administration (VHA).
METHODS: VISN16 electronic medical records for 10/2002-08/2005 were used to identify
patients with schizophrenia who received a new episode of SGA treatment after 10/2003, in
which the VISN 16 baseline MetMon program was implemented. Patients who underwent
MetMon (MetMon+: either blood glucose or lipid testing records) were compared with patients
who did not (MetMon-), on patient characteristics and resource utilization in the year prior to
index treatment episode. A parsimonious logistic regression was used to identify predictors
for MetMon+ with adjusted odds ratios (OR) and 95% confidence intervals (CI). RESULTS:
Out of 4,709 patients, 3,568 (75.8%) underwent the baseline MetMon. Compared with the
MetMon- group, the MetMon+ patients were found more likely to have baseline diagnoses or
mediations for diabetes (OR [CI]: 2.336 [1.846-2.955]), dyslipidemia (2.439 [2.029-2.932]),
and hypertension (1.497 [1.287-1.743]), substance use disorders (1.460 [1.257-1.696]), or to
be recorded as obesity (2.052 [1.724-2.443]). Increased likelihood for monitoring were
positively associated with number of antipsychotics during the previous year (FGA: 1.434
[1.129-1.821]; SGA: 1.503 [1.290-1.751]). Other significant predictors for monitoring were
more augmentation episodes (1.580 [1.145-2.179]), more outpatient visits (1.007 [1.0021.013])), hospitalization days (1.011 [1.007-1.015]), and longer duration of antipsychotic use
(1.001 [1.001-1.001]). Among the MetMon+ group, approximately 38.9% patient had
metabolic syndrome. DISCUSSION: This wide time window of 180 days, although congruent
with the VHA guidelines for the baseline MetMon process, needs to be re-evaluated and
narrowed down, so that optimally the monitoring event occurs at the time of receiving a new
episode of SGA treatment. Future research will examine whether or not patients prescribed
an SGA are assessed for metabolic syndrome following the index episode of antipsychotic
therapy, and whether or not such baseline and follow-up monitoring programs in routine care
are cost-effective. CONCLUSION: The baseline MetMon has been performed for a majority of
the VISN 16 patients with schizophrenia prior to index SGA over the study period. Compared
with MetMon- group, MetMon+ patients were more likely to be obese and manifest a more
severe illness profile.
Publication Type Journal: Article
Journal Name BMC psychiatry
Volume 9
Page 80
Year of Publication 2009
Date of Publication 2009